Eledon Pharmaceuticals (ELDN) Cost of Revenue (2024 - 2026)

Eledon Pharmaceuticals has reported Cost of Revenue for 3 years, with the latest figure at $7.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 366.23% year-over-year to $7.8 million; the trailing twelve-month figure through Mar 2026 stood at $21.1 million (up 78.08% YoY), and the FY2025 full-year result was $15.0 million, up 20.29% from the prior year.
• Cost of Revenue for Q1 2026 stood at $7.8 million, down from $9.5 million in the prior quarter.
• The five-year high for Cost of Revenue was $9.5 million in Q4 2025, with the low at $1.3 million in Q1 2024.
• Historically, Cost of Revenue has averaged $3.8 million across 3 years, with a median of $2.0 million in 2025.
• Annual changes were most pronounced in 2025 — Cost of Revenue plunged 55.81% — and 2026, when it soared 366.23%.
• Eledon Pharmaceuticals' Cost of Revenue stood at $4.6 million in 2024, then soared by 104.76% to $9.5 million in 2025, then declined by 17.73% to $7.8 million in 2026.
• The last three Cost of Revenue figures came in at $7.8 million (Q1 2026), $9.5 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.